10X Genomics

What 10X Genomics does

10x Genomics is a publicly traded life-science tools company (NASDAQ: TXG) that develops single-cell and spatial biology platforms used by academic researchers, biopharmaceutical companies, and clinical institutions to profile gene expression, protein expression, and chromatin state at single-cell and subcellular resolution. Its instrument portfolio centers on four platforms: Chromium Single Cell (droplet-based single-cell multiomics powered by GEM-X microfluidic technology with up to 80% cell recovery and 95% usable reads), Atera In Situ (whole-transcriptome spatial platform launched April 2026 with throughput of up to 800 1 cm² samples per year), Xenium In Situ (high-plex subcellular imaging of up to 5,000 RNA targets), and Visium Spatial (NGS-based spatial gene expression with the CytAssist instrument). Chemistries include Flex Apex (plate-based multiplexing of up to 384 samples or 100 million cells per week for FFPE and fixed whole blood), Universal 3'/5', and Epi multiome assays, complemented by free software pipelines (Cell Ranger, Space Ranger, Loupe Browser, Xenium Explorer) and cloud analysis tools.

The company makes money primarily by selling capital instruments and a recurring stream of consumables (reagents, assay kits, panels, and microfluidic chips) that drive the bulk of revenue; consumables grew to $598.7M in FY2025 while instruments declined 39% as customers worked through installed-base capacity. Distribution combines a global direct enterprise sales force for large pharmaceutical and academic accounts, a regional distributor network including Asia-Pacific, an e-commerce store for mid-market consumables purchases, and service-provider partners such as Macrogen/Psomagen that operate 10x instruments on behalf of researchers who do not want to buy capital equipment. Customers include biopharmaceutical companies (drug discovery, biomarker, and trial-design applications), academic and research institutions (cancer, immunology, neuroscience, developmental biology), and an emerging clinical healthcare segment, with a pipeline of major partnerships including the STELA atlas with Bioptimus, the Billion Cells Project with the Chan Zuckerberg Initiative, and the ImmuneScape initiative with CareDx.

10x Genomics is incorporated in the United States, headquartered in Pleasanton, California, and employs 1,001-5,000 people. It went public on NASDAQ in September 2019 and has since used M&A to extend its technology footprint, acquiring Spatial Transcriptomics (2018), EPINOMICS (2018), ReadCoor (2020), CARTANA (2020), Tetramer Shop (2021), Scale Biosciences (2025), and Proteintech Genomics (2026) to add spatial, epigenomic, and proteomic capabilities.

Name

10X Genomics

Legal name

10x Genomics, Inc.

Website

https://10xgenomics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

10x Genomics (NASDAQ: TXG) develops single-cell and spatial biology instruments and consumables — Chromium, Atera, Xenium, and Visium — used by academic, biopharmaceutical, and clinical researchers to profile gene and protein expression at single-cell resolution.

Ownership category

akta.pro rank

Product category

Life Sciences Research Instrumentation

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Single cell analysis
• Spatial transcriptomics
• Genomics instrumentation
• Multiomics platforms
• Life sciences reagents

Headquarters

HQ city

Pleasanton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Instrument Sales: Sale of capital equipment including Chromium instruments (X Series, Controller, Connect), Atera spatial platform, Xenium Analyzer, and Visium CytAssist. Instrument revenue declined 39% year-over-year in FY2025.
2. Consumables: Recurring revenue from reagents, assay kits, and consumables for single cell and spatial biology assays including Flex, Universal 3'/5', Epi kits, Xenium panels, and Visium reagents. Consumables revenue grew 3% in FY2025 to $598.7 million (underlying, excluding patent settlement).
3. Software and Analysis: Revenue from software products including Cell Ranger, Space Ranger, Loupe Browser, Xenium Explorer, and cloud-based analysis tools. Software includes free pipelines with premium features and cloud services.
4. CLIA Laboratory Services: Future revenue stream from plans to build CLIA-certified laboratory for clinical diagnostic services, supporting assay implementation and clinical sample processing.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

10X Genomics develops and commercializes integrated platforms for single-cell and spatial biology, combining proprietary instruments (Chromium, Atera, Xenium, Visium), assay chemistries (Flex, Universal 3'/5', Epi), and software (Cell Ranger, Loupe Browser, Cloud Analysis, Space Ranger, Xenium Explorer). Products enable researchers to profile gene expression at single-cell resolution across thousands of samples, supporting cancer research, immunology, neuroscience, drug discovery, and translational medicine applications. Revenue is generated through instrument sales and a recurring consumables and software stream tied to installed platforms.

Product overview

10x Genomics is a life science technology company offering a comprehensive portfolio of single-cell and spatial biology platforms. The product portfolio centers on four core instrument platforms: Chromium Single Cell (droplet-based single-cell analysis), Atera In Situ (next-generation whole-transcriptome spatial platform), Xenium In Situ (high-plex spatial imaging), and Visium Spatial (NGS-based spatial analysis). These are complemented by assay chemistries including Flex Apex (probe-based, plate-multiplexed), Universal 3'/5' (transcriptome-based), and Epi kits for chromatin analysis. A comprehensive software ecosystem includes Cell Ranger, Cloud Analysis, Loupe Browser, Space Ranger, and Xenium Explorer for data processing and visualization. The company serves academic, translational, and biopharmaceutical researchers across cancer research, immunology, neuroscience, and developmental biology applications.

Differentiator

Problem solved

Functional benefit

Brands

• Atera: Next-generation in situ spatial biology platform for whole-transcriptome spatial analysis with single-cell sensitivity at scale.
• Flex Apex
• Chromium
• Xenium
• Visium

Products and services

• Chromium Single Cell

Quantifiable outcome

• Up to 80% cell recovery efficiency
• +5 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability6 records

Feature6 records

Partnerships

17 partnerships are on record, tiered core, minor and flagship.

• Cleveland CliniccoreStrategic or Co-development Partner · 17 June 2026Multi-year research collaboration focused on bladder cancer diagnostics using single-cell, spatial transcriptomic, and protein profiling technologies to build multimodal cancer datasets linking molecular data with clinical outcomes
• Proteintech GenomicscoreTechnology or Integration · 9 June 2026Acquisition expanding 10x Genomics' proteomics capabilities, adding the Human Discovery Panel and antibody-based single-cell protein panels compatible with Flex chemistry workflows for enhanced multiomic analysis
• AnthropiccoreTechnology or Integration · 31 March 2026Integration of 10x Genomics analysis tools into Anthropic's Claude for Life Sciences platform, enabling AI-powered analysis of single cell and spatial biology data
• BioptimuscoreStrategic or Co-development Partner · 25 March 2026Strategic partnership anchoring the STELA spatial biology initiative to profile up to 100,000 patient tissue specimens across US, Europe, and Asia using the Xenium platform, creating data backbone for Bioptimus's M-Optimus world model of biology
• Broad Clinical LabscoreStrategic or Co-development Partner · 25 March 2026Partnership in STELA initiative contributing high-throughput data generation capabilities for the 100,000-specimen spatial biology atlas spanning three continents
• PerturbAIminorStrategic or Co-development Partner · 17 March 2026Collaboration providing 10x Genomics technology for PerturbAI's 8 million-cell brain-wide CRISPR atlas generated using in vivo Perturb-seq technology for AI-driven drug discovery
• RochecoreTechnology or Integration · 26 February 2026Partnership to develop single-cell kits for Roche's AXELIOS 1 sequencer platform, integrating 10x Genomics technology into Roche's diagnostic ecosystem
• PharosAIflagshipStrategic or Co-development Partner · 4 February 2026UK consortium partnership using Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets from archived NHS samples, backed by £18.9 million UK government funding, initially focusing on breast cancer expanding to lung and pancreatic cancer through 2027
• Dana-Farber Cancer InstituteflagshipStrategic or Co-development Partner · 12 January 2026Multi-year collaboration analyzing tumor samples from patients with major solid cancers using Chromium Flex single cell assay and Xenium spatial platform to identify biological features associated with treatment response and resistance
• Brigham and Women's HospitalflagshipStrategic or Co-development Partner · 12 January 2026Study analyzing blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using Chromium Flex single-cell assay to identify immune signatures for personalized autoimmune disease management
• Cancer Research InstituteflagshipStrategic or Co-development Partner · 12 January 2026Multi-phase collaboration building one of the world's largest AI-driven immuno-oncology datasets profiling over 20,000 samples to map the immune landscape of cancer and accelerate immunotherapy discovery
• CareDxflagshipStrategic or Co-development Partner · 7 January 2026Launch of ImmuneScape multiomics research initiative to decode transplant rejection and drug response using Xenium spatial and Chromium Flex single cell platforms, building on CareDx's HistoMap Kidney product
• Arc InstituteflagshipStrategic or Co-development PartnerVirtual Cell Atlas collaboration generating 300M+ cell CRISPR perturbational dataset using Flex technology to fuel AI cell models predicting cellular responses for therapeutic target discovery
• Chan Zuckerberg InitiativeflagshipStrategic or Co-development PartnerBillion Cells Project creating landmark single cell dataset using Chromium technology to deepen understanding of cellular behavior and gene function for AI model training
• OwkinflagshipStrategic or Co-development PartnerMOSAIC pan-cancer spatial transcriptomics initiative using Visium and Flex technologies to enable AI-based therapeutic prediction modeling with 7,000 FFPE tissues
• A*STAR Genome Institute of SingaporeflagshipStrategic or Co-development PartnerTISHUMAP study using Xenium platform for large-scale spatial omics enabling drug target discovery with 2,500 FFPE tissues
• Xaira TherapeuticsflagshipStrategic or Co-development PartnerX-Atlas/Orion project generating largest publicly available Perturb-seq atlas targeting all human protein-coding genes for foundational model training using Universal 5' technology with 8M cells

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NanoString Technologies (acquired by Bruker): Direct competitor in spatial transcriptomics through the CosMx SMI (single-cell) and GeoMx (tissue) platforms. Now operating under Bruker's Spatial Biology division, NanoString is 10x's principal head-to-head rival in the spatial biology market.
• Vizgen: Direct competitor in spatial transcriptomics with the MERFISH platform, offering high-plex in situ gene expression profiling. Competes directly with 10x's Xenium and Atera platforms for translational and academic spatial biology customers.
• Akoya Biosciences: Spatial biology competitor offering the PhenoCycler (CODEX) multiplexed spatial proteomics platform and Phenoptics tissue imaging solutions. Competes with 10x's Xenium and Visium in immuno-oncology and translational research workflows.
• Bio-Techne: Competitor in single-cell and spatial consumables, including the RNAscope in situ hybridization product line and ProteinSimple instruments. Overlaps with 10x on consumables sold to academic and translational research customers.
• Standard BioTools (formerly Fluidigm): Single-cell analysis competitor with the Hyperion imaging mass cytometry and legacy CyTOF / mass cytometry products. Competes with 10x Chromium in immunology and oncology research, especially in multiomic protein profiling.

Broad incumbents

• Illumina: Dominant sequencing platform provider that is both a critical downstream dependency for 10x Chromium/Visium workflows and a broader competitor through its own single-cell and spatial initiatives (e.g., Illumina Connected Multiomics). Strategic partner and ecosystem competitor.
• Revvity (formerly PerkinElmer Life Sciences): Diversified life science tools and reagents provider with overlapping offerings in spatial biology, genomics workflows, and clinical diagnostics. Competes with 10x in reagent and consumables categories through its life sciences segment.
• Pacific Biosciences: Long-read sequencing platform provider with emerging single-cell and HiFi sequencing offerings. Competes for genomics research budgets and offers an alternative to Illumina-based 10x workflows for certain applications.
• Bruker Corporation: Acquired NanoString Technologies and offers spatial biology products (CosMx, GeoMx, CellScape) directly competing with 10x's Xenium and Atera. A diversified life science tools incumbent with broader mass spectrometry and proteomics offerings.

Emerging players

• Element Biosciences: Emerging sequencing platform competitor with the AVITI system, offering lower-cost sequencing that could disrupt the Illumina-anchored 10x ecosystem. Increasingly competitive in academic and translational sequencing markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/10xgenomics
• YouTubeyoutube.com/c/10xGenomics
• Facebookfacebook.com/10xGenomics
• LinkedInlinkedin.com/company/10xgenomics
• Instagraminstagram.com/10xgenomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 10X Genomics